Viktoria-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in PIK3CA Wild-Type

09 Mar 20264 min read0 viewsJournal Feed

GIST

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 09 Mar 2026. The item focuses on VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer. Review the original article for the full source wording and details.

Clinical Editorial

Summary

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 09 Mar 2026.

The item focuses on VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

ClinicalTrialsRelated by Conditionbreast cancer

Source

Journal of Clinical Oncology (JCO)

Viktoria-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in PIK3CA Wild-Type

GIST

Clinical Editorial

Summary

Source Reference

Related by Condition/Drug

Mapping and Quantifying Lymphatic Drainage of the Arm's Alternate Pathway

CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer

CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer

FDG-PET for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer

OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC

OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC